Mitsubishi Tanabe Pharma Corp - Company Profile
Powered by 
All the data and insights you need on Mitsubishi Tanabe Pharma Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Mitsubishi Tanabe Pharma Corp Strategy Report
- Understand Mitsubishi Tanabe Pharma Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Mitsubishi Tanabe Pharma Corp Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Mitsubishi Tanabe Pharma Corp Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 08 Dec 2021 | Lorem |
| Mitsubishi Tanabe Pharma’s ND0612 holds Phase III success uncertainty but its noninvasive delivery draws rescue therapy interest in Parkinson’s disease, even over oral approaches, experts say | 20 Nov 2019 | Shuan Sim |
| Akebia's vadadustat in CKD with anemia will focus on secondary endpoint values for future payer discussions- CEO | 15 Jan 2018 | Jennifer C. Smith-Parker |
| NeuroSense Therapeutics seeks CRO to help run Phase II ALS trial initiating in 3Q18 – CEO | 22 Nov 2017 | Christina Hwang |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer